Ready-to-use hiPSC-Derived Cardiac Organoids

用户评价
货号-规格
价格
Qty.
CIPO-HWL01-5organoids (1organoid X 5)
询价
CIPO-HWL01-20organoids (1organoid X 20)
询价
CIPO-HWL01-100organoids (1organoid X 100)
询价
合计0件 产品金额¥ 0

产品详情

  • 产品描述(Product Details)

    Human iPSC-Derived Cardiac Organoids (Cat. No. CIPO-HWL01) are three-dimensional in vitro models that recapitulate key structural and functional features of human cardiac tissue. These organoids are generated from the human iPSC line ATCC-HYR0103 under ultra-low attachment (ULA) culture conditions using a self-assembly cardiac differentiation workflow. Human iPSC-Derived Cardiac Organoids are shipped at ambient temperature and provided in a ready-to-use format for functional assessment and downstream applications. These organoids typically form cavity-containing cardiac structures, exhibit spontaneous contractile activity, and express markers associated with cardiomyocytes (cTnT), fibroblasts (VIM), and endothelial cells (CD31). Human iPSC-Derived Cardiac Organoids are intended for use with Human iPSC-Derived Cardiac Organoid Maintenance Medium (RIPO-HWM01). They are recommended for use between DIV 25 and DIV 50.

  • 产品特征(Product Specification)

    The cardiac organoids are ready-to-use organoids that are delivered in shipping medium and has to go through a recovery period according to instruction before starting any test or experiment.

  • 存储(Storage)

    After recovery, please store the organoid in its maintenance medium under the correct incubation condition and medium changing process.

  • 运输(Shipping)

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • *请注意,为了支持完整的类器官培养和维持过程,本产品必须与hiPSC-Derived Cardiac Organoid Maintenance Kit (Cat. No. RIPO-HWM01)一起使用。您可以点击此链接获取产品信息。
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 产品示意(Product Diagram)

     Organoids PRODUCT DIAGRAM

    Diagram of cardiac organoid differentiation.

验证(Validation)
  • Marker Expression

     Organoids MARKER EXPRESSION

    Cardiac Lineage Marker Expression in hiPSC-Derived Cardiac Organoids.
    Day 30 human iPSC-derived cardiac organoids expressed key cardiac lineage markers, including cardiomyocyte markers cTnT (QC), MYL7, and MYL2; the fibroblast-associated marker Vimentin (QC); the endothelial marker CD31 (QC); and the smooth muscle marker α-SMA. These results indicate the presence of multiple cardiac-relevant cell populations within the 3D organoid structure.

    Protocol
  • Organoid Activity

     Organoids ORGANOID ACTIVITY

    Intra-batch morphological consistency
    Cardiac organoids within the same batch showed comparable growth and morphological progression from Day 0 to Day 30, with low coefficients of variation (CVs) in diameter (QC), area, and circularity.

    Protocol
     Organoids ORGANOID ACTIVITY

    Inter-batch morphological consistency
    Cardiac organoids from three independent batches showed comparable morphology, diameter (QC), area, and circularity, with low coefficients of variation (CVs).

    Protocol
  • Organoid Application

     Organoids ORGANOID APPLICATION

    Spontaneous calcium transients in hiPSC-derived cardiac organoids
    Representative calcium fluorescence image and ΔF/F₀ traces from hiPSC-derived cardiac organoids (in video). Spontaneous calcium transients were detected over a 60-s recording period and showed reproducible rhythmic activity. Quantification of a representative transient demonstrated a time to peak (TTP) of 0.5 ± 0.2 s and a calcium transient duration at 90% decay (CaD90) of 0.73 s. Scale bar: 500 μm.

    Protocol
     Organoids ORGANOID APPLICATION

    Electrophysiological profiling of hiPSC-derived cardiac organoids by MEA
    MEA recordings (QC) showed stable electrical activity across multiple electrodes in cardiac organoids. Following treatment with E-4031, a hERG/IKr potassium channel blocker, and nifedipine, an L-type calcium channel blocker, the organoids showed compound-related changes in MEA-derived electrophysiological readouts, supporting the potential use of this model for cardiac functional and safety assessment.

    Protocol

用户评价
发表评论

前沿进展

 
联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价